new research topics in pharmaceutics

Top five research articles of 2020

Despite the significant challenges this year has posed, The Pharmaceutical Journal  has continued to publish high-quality peer-reviewed research.

Our researchers have made a range of investigations — from evaluating pharmacist interventions using the Simpler tool in Malaysia , to a pharmacist-led virtual thiopurine clinic to support people with inflammatory bowel disease and auto-immune hepatitis, here in the UK.

We have some exciting research coming up in 2021, but in case you missed them the first time around, here are the top five most popular research articles of 2020:

5. Misuse of prescription and over-the-counter drugs to obtain illicit highs: how pharmacists can prevent abuse

Use of prescription and over-the-counter drugs for recreational purposes is increasing, and this perspective article collates the existing literature to provide an in-depth overview of the misuse and diversion of a range of drugs with psychoactive potential, including gabapentinoids, antihistamine drugs and loperamide.

4. Effective detection and management of hypertension through community pharmacy in England

Community pharmacists can play a big role in managing hypertension — from the identification of medication-related problems, to providing lifestyle advice. Despite this, they are not routinely involved in structured hypertension management or screening programmes. So, this review summarises the evidence to recommend the roll-out of a community pharmacy-led hypertension management service.

3. Recent advances in the oral delivery of biologics

Oral administration of medicines is often preferred by patients for its convenience, but, for biologics, the gastrointestinal tract poses challenges for administering in this way. This review discusses the advantages and limitations of several novel drug delivery strategies, and highlights the work to be done to put this technology into clinical practice.

2. Immuno-oncology agents for cancer therapy

Immuno-oncology is a novel treatment that works by conditioning the body’s immune cells to recognise and kill cancer cells — combining this treatment with conventional therapies has led to promising improvements in patient outcomes. This review looks at the range of immuno-oncology agents, and how problems such as their toxicity and high cost can be overcome.

1. Investigational treatments for COVID-19

The emergence of COVID-19 resulted in a global research effort to find effective treatment options to relieve healthcare burdens and, ultimately, save lives. In June 2020, this rapid review summarised the clinical trials and treatment evidence at the time.

Check out The Pharmaceutical Journal’ s   ‘Everything you should know about the coronavirus outbreak’ for the latest on this continually evolving situation.

Find the full catalogue of articles in our research section .

Call for submissions

In 2021, The Pharmaceutical Journal will keep adding to the evidence base with review, perspective and research articles. If you have undertaken research into innovations and initiatives that can improve pharmacy services and administration, the pharmacological management of disease, or advances in drug development, please submit your article for consideration by email to: [email protected]

You may also be interested in

Martin Sawer: ‘NHS hospitals owe wholesalers millions of pounds in overdue invoices’

NICE recommends tenecteplase for treating acute ischaemic stroke patients

Best practice principles for inclusive care of transgender and non-binary patients

• Pharmacy and Clinical Pharmacology

Explore JAMA Network Open’s collection on clinical pharmacy and pharmacology, including topics in drug safety and development, pharmacogenetics, and more.

Publication

Article type.

This cohort study examines whether early high-dose recombinant human erythropoietin is associated with better executive functions and processing speed among school-aged children who were born very preterm.

• Reflections on Neonatal Erythropoietin Neuroprotection Studies JAMA Network Open Opinion September 10, 2024 Child Development Hematology Pediatrics Clinical Pharmacy and Pharmacology Neonatology Full Text | pdf link PDF open access
• Managing Drug-Drug Interactions—So Many Drugs, So Little Evidence JAMA Network Open Opinion September 6, 2024 Coronavirus (COVID-19) Clinical Pharmacy and Pharmacology Rheumatology Adverse Drug Events Full Text | pdf link PDF open access

This randomized clinical trial evaluates the efficacy and safety of dual antiplatelet therapy with clopidogrel and aspirin compared with aspirin alone among patients in China with mild ischemic stroke or transient ischemic attack when initiated up to 72 hours after symptom onset.

This secondary analysis of a randomized clinical trial examines gastrointestinal adverse events due to interactions between colchicine and other medications in individuals with COVID-19.

This cross-sectional study investigates the association of medical and recreational legalization of cannabis and dispensary openings with the dispensing of psychotropic medications used to treat mental health disorders in the US.

• Skepticism Calibration Disorder—The New Public Health Crisis JAMA Network Open Opinion September 4, 2024 Health Policy Nutrition, Obesity, Exercise Complementary and Alternative Medicine Clinical Pharmacy and Pharmacology Infectious Diseases Full Text | pdf link PDF open access

This survey study examines responses from community members and pharmacists for a potential bias in intuitive reasoning (post hoc bias) when asked for recommendations regarding a hypothetical scenario describing a patient who experiences marginal improvement in symptoms after a dubious treatment.

This cohort study evaluates the association of current, recent, and no hydroxychloroquine use with the risk of myocardial infarction, stroke, and other thromboembolic events in patients with systemic lupus erythematosus.

This cross-sectional study examines racial and ethnic disparities in take-home methadone use among Medicare beneficiaries with opioid use disorder following the Substance Abuse and Mental Health Services Administration’s policy change in March 2020.

This survey study assesses the effectiveness of drug advertisement to shape perception of the benefits and risks of and personal willingness to use and recommend an advertised drug.

This cohort study evaluates whether hormone therapy use is associated with discrepancies in chronological and biological age among postmenopausal women, considering socioeconomic status as a potential modifying factor.

This cross-sectional study examines whether implementation of pharmacy naloxone standing order dispensing was associated with lower community-level opioid fatality rates in Massachusetts.

• First-Generation Antihistamines and Seizures in Young Children JAMA Network Open Opinion August 28, 2024 Neurology Clinical Pharmacy and Pharmacology Toxicology Adverse Drug Events Pharmacoepidemiology Full Text | pdf link PDF open access

This cohort study uses a case-crossover design to investigate the association between prescription of first-generation antihistamines and seizures in young children using a nationwide population-based claims dataset.

This mendelian randomization study uses mendelian randomization to investigate potential causal relationships between perturbing maternal genetic variants influencing antihypertensive drug targets and perinatal outcomes among offspring.

This cohort study assesses the association between the risk of fall-related injuries and first-line treatments for depression among older US adults with depression.

This cross-sectional study examines the association of availability of primary care practitioners and level of socioeconomic vulnerability with risk of pharmacy deserts in regions of the US.

This case control study evaluates potential signals for suicidal and self-injurious adverse drug reactions associated with semaglutide and liraglutide.

• GLP-1 Receptor Agonists and Suicidality—Caution Is Needed JAMA Network Open Opinion August 20, 2024 Clinical Pharmacy and Pharmacology Global Health Adverse Drug Events Diabetes Diabetes and Endocrinology Full Text | pdf link PDF open access

Select Your Interests

Customize your JAMA Network experience by selecting one or more topics from the list below.

• Academic Medicine
• Acid Base, Electrolytes, Fluids
• Allergy and Clinical Immunology
• American Indian or Alaska Natives
• Anesthesiology
• Anticoagulation
• Art and Images in Psychiatry
• Artificial Intelligence
• Assisted Reproduction
• Bleeding and Transfusion
• Caring for the Critically Ill Patient
• Challenges in Clinical Electrocardiography
• Climate and Health
• Climate Change
• Clinical Challenge
• Clinical Decision Support
• Clinical Implications of Basic Neuroscience
• Clinical Pharmacy and Pharmacology
• Complementary and Alternative Medicine
• Consensus Statements
• Coronavirus (COVID-19)
• Critical Care Medicine
• Cultural Competency
• Dental Medicine
• Dermatology
• Diabetes and Endocrinology
• Diagnostic Test Interpretation
• Drug Development
• Electronic Health Records
• Emergency Medicine
• End of Life, Hospice, Palliative Care
• Environmental Health
• Equity, Diversity, and Inclusion
• Facial Plastic Surgery
• Gastroenterology and Hepatology
• Genetics and Genomics
• Genomics and Precision Health
• Global Health
• Guide to Statistics and Methods
• Hair Disorders
• Health Care Delivery Models
• Health Care Economics, Insurance, Payment
• Health Care Quality
• Health Care Reform
• Health Care Safety
• Health Care Workforce
• Health Disparities
• Health Inequities
• Health Policy
• Health Systems Science
• History of Medicine
• Hypertension
• Images in Neurology
• Implementation Science
• Infectious Diseases
• Innovations in Health Care Delivery
• JAMA Infographic
• Law and Medicine
• Leading Change
• Less is More
• LGBTQIA Medicine
• Lifestyle Behaviors
• Medical Coding
• Medical Devices and Equipment
• Medical Education
• Medical Education and Training
• Medical Journals and Publishing
• Mobile Health and Telemedicine
• Narrative Medicine
• Neuroscience and Psychiatry
• Notable Notes
• Nutrition, Obesity, Exercise
• Obstetrics and Gynecology
• Occupational Health
• Ophthalmology
• Orthopedics
• Otolaryngology
• Pain Medicine
• Palliative Care
• Pathology and Laboratory Medicine
• Patient Care
• Patient Information
• Performance Improvement
• Performance Measures
• Perioperative Care and Consultation
• Pharmacoeconomics
• Pharmacoepidemiology
• Pharmacogenetics
• Physical Medicine and Rehabilitation
• Physical Therapy
• Physician Leadership
• Population Health
• Primary Care
• Professional Well-being
• Professionalism
• Psychiatry and Behavioral Health
• Public Health
• Pulmonary Medicine
• Regulatory Agencies
• Reproductive Health
• Research, Methods, Statistics
• Resuscitation
• Rheumatology
• Risk Management
• Scientific Discovery and the Future of Medicine
• Shared Decision Making and Communication
• Sleep Medicine
• Sports Medicine
• Stem Cell Transplantation
• Substance Use and Addiction Medicine
• Surgical Innovation
• Surgical Pearls
• Teachable Moment
• Technology and Finance
• The Art of JAMA
• The Arts and Medicine
• The Rational Clinical Examination
• Tobacco and e-Cigarettes
• Translational Medicine
• Trauma and Injury
• Treatment Adherence
• Ultrasonography
• Users' Guide to the Medical Literature
• Vaccination
• Venous Thromboembolism
• Veterans Health
• Women's Health
• Workflow and Process
• Wound Care, Infection, Healing
• Register for email alerts with links to free full-text articles
• Access PDFs of free articles
• Manage your interests
• Save searches and receive search alerts

• Frontiers in Chemistry
• Analytical Chemistry
• Research Topics

Recent Advances in Pharmaceutical Analysis: Applications and New Challenges for the Quality of Medicines

Total Downloads

Total Views and Downloads

About this Research Topic

Analytical chemistry in pharmaceutical analysis deals with the investigation of bulk drug materials, active pharmaceutical ingredients, intermediates, drug products, including their impurities and degradation products, to address the different qualitative and quantitative descriptors of medicines. This task ...

Keywords : Quality of medicines, chromatography, mass spectrometry, spectroscopy, multivariate analysis, sample preparation

Important Note : All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

Topic Editors

Topic coordinators, recent articles, submission deadlines.

Participating Journals

Manuscripts can be submitted to this Research Topic via the following journals:

total views

• Demographics

No records found

total views article views downloads topic views

Top countries

Top referring sites, about frontiers research topics.

With their unique mixes of varied contributions from Original Research to Review Articles, Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author.

Journals, books & databases

• Our journals

RSC Pharmaceutics

Leading the way in drug delivery, formulation and pharmaceutical technology

What would you like to know about RSC Pharmaceutics?

Editor-in-Chief: Yvonne Perrie

Impact factor: n/a

Gold open access, APCs currently waived

Time to first decision (peer-reviewed only): 47.0 days***

Time to first decision (all decisions): 15 days**

Submit your manuscript

Journal scope

Sign up for regular email alerts

View all journal metrics

How can chemistry help build a healthier world?

Chemistry is at the centre of our existence and offers transformative solutions to many global challenges, including health. RSC Pharmaceutics acknowledges how chemistry and related disciplines can make a big difference. This impactful journal provides you with a platform to publish crucial research on pharmaceutics.

This is an area of technical opportunity. We are interested in papers that cover emerging technologies and techniques in pharmaceutics, including drug delivery, precision medicine, and enhanced drug targeting. If your research pushes the boundaries of current thinking, then we want to hear from you.

The publications in RSC Pharmaceutics have the potential to drive real change in worldwide health. Our gold open access policy elevates this potential, making sure that everyone around the planet can access and benefit from our publications. We are also covering article processing charges until mid-2026, so you can publish with us for free. Let’s get started.

Introducing our Editor-in-Chief

RSC Pharmaceutics is a new gold open access journal leading the way in the field of Pharmaceutics. This journal publishes research focused on formulating a drug into a medicine, with the intention of achieving controllable drug delivery with high efficacy.

Research published in RSC Pharmaceutics promotes step-change science in the field of Pharmaceutics, and, as such, all submissions must show clear innovation, be scientifically sound, and have a significant impact on the field. Research sharing new scientific findings from across the areas of chemistry, materials science, biomedical sciences, pharmaceutics and drug delivery are all welcomed.

Topics include but are not limited to :

• Formulation and design of medicines
• Design and characterization of correct dosage forms
• Physicochemical and biological properties of drugs and their carriers
• Drug delivery devices and their mechanisms of release

See who's on the team

Meet  RSC Pharmaceutics 's Editor-in-Chief and board members.

Editorial members

Editor-in-chief University of Strathclyde, UK

Associate Editor University of Strathclyde, UK

Associate Editor China Pharmaceutical University, China

Associate Editor Florida International University, USA

Associate Editor Technion - Israel Institute of Technology, Israel, & Houston Methodist Academic Institute, USA

Laura Fisher , Executive Editor, ORCID: 0000-0002-8761-0383

Sarah Rainford , Deputy Editor

Becky Webb , Editorial Production Manager

Namita Datta , Assistant Editor

Anoushka Handa , Assistant Editor

Patrick de Jongh , Assistant Editor, ORCID: 0000-0003-4201-0824

Claire Mitchell , Assistant Editor, ORCID: 0000-0003-3127-2730

Karina Webster , Editorial Assistant

Rob Griffiths , Publishing Assistant

Neil Hammond , Publisher, ORCID: 0000-0001-6390-8874

Article types

RSC Pharmaceutics publishes:

Communications

Full papers.

• Perspectives

Our Communication format is ideally suited to short studies - which can be preliminary in nature - that are of such importance that they require accelerated publication.

Communications must contain original and highly significant work whose interest to the RSC Pharmaceutics readership and high novelty warrants rapid publication. Authors should supply with their submission a justification of why the work merits urgent publication as a Communication. Referees will be asked to judge the work on these grounds.

Communications are given high visibility within the journal as they are published at the front of an issue. Communications will not normally exceed the length of five printed journal pages.

Full papers in RSC Pharmaceutics present original research that has not been published previously. Although there is no page limit for Full papers, appropriateness of length to content of new science will be taken into consideration.

Reviews, Perspectives & Opinions

These are normally commissioned by the editorial board and editorial office, although suggestions are most welcome – proposals (comprising the title, short synopsis, and key references) should be sent by email to the Editors at [email protected] .

Reviews, Perspectives and Opinions must be high-quality, authoritative, state-of-the-art accounts of a particular facet of pharmaceutics or pharmaceutical technology. They should be timely and add to the existing literature, rather than duplicate existing articles, and should be easily comprehensible and of general interest to the journal's wide readership. All Reviews, Perspectives and Opinions undergo a rigorous and full peer review procedure, in the same way as regular research papers.

All review content should consist of original text and interpretation, avoiding any direct reproduction. If a significant amount of other people's material is to be used, either textual or image-based, permission must be sought by the author in accordance with copyright law and must be made clear in the manuscript.

Review articles report a detailed, balanced and authoritative current account of the selected research field. Please note that Reviews in RSC Pharmaceutics may not contain any original research.

Perspectives are contributions offering the personal account or critical analysis of a topic of current interest. They present a state-of-the-art account with an emphasis on future challenges and opportunities. Perspectives may contain some unpublished research and have no strict length requirements, and they should be written to their natural length.

Opinions provide a short, personal viewpoint or hypothesis on a topic of current interest to the scientific community. They can be speculative in nature and stimulate counter-opinion, provided that they are not defamatory to the work of others. They should contain rigorous, evidence-backed scientific justification, and bring significant and valuable insights to the field.

Comments and Replies are a medium for the discussion and exchange of scientific opinions between authors and readers concerning material published in RSC Pharmaceutics .

For publication, a Comment should present an alternative analysis of and/or new insight into the previously published material. Any Reply should further the discussion presented in the original article and the Comment. Comments and Replies that contain any form of personal attack are not suitable for publication.

Comments that are acceptable for publication will be forwarded to the authors of the work being discussed, and these authors will be given the opportunity to submit a Reply. The Comment and Reply will both be subject to rigorous peer review in consultation with the journal’s Editorial Board where appropriate. The Comment and Reply will be published together.

Author Guidelines

For general guidance on preparing an article please visit our Prepare your article page , the content of which is relevant to all our journals. Please note that RSC Pharmaceutics does not require authors to submit using a specific template, but there are templates available if you wish to use them.

To learn more about the Royal Society of Chemistry's policies and processes, including licensing, experimental data guidelines, peer review and formatting, please refer to our Resources for authors and Experimental data guidelines pages.

Peer review and editorial process

All articles published in RSC Pharmaceutics are subject to external peer review by anonymised experts in the field and all manuscripts submitted are handled by a team of internationally recognised Associate Editors, who are all practicing scientists in the field.

The peer review for all articles submitted to the journal consists of the following stages:

Phase 1 : Your manuscript is initially assessed by an associate editor to determine its suitability for peer review.

Phase 2 : If the manuscript passes the initial assessment process, the associate editor solicits recommendations from at least two anonymous reviewers who are experts in the field. They will provide a report along with their recommendation.

Phase 3 : The associate editor handling your manuscript makes a decision based on the reviewer reports received. In the event that no clear decision can be made, another reviewer will be consulted.

RSC Pharmaceutics is committed to a rigorous peer review process and expert editorial oversight for all published content. Please refer to our processes and policies for full details including our appeals procedure.

Transparent peer review

To support increased transparency, we offer authors the option of transparent peer review, where the editor’s decision letter, reviewers’ comments and authors’ response for all versions of the manuscript will be published alongside the article under an Open Access Creative Commons licence (CC-BY) . Reviewers are anonymous unless they choose to sign their report.

Find out more about our transparent peer review policy .

Publication frequency

Articles accepted for publication in  RSC Pharmaceutics are published online with citeable DOIs as Advance Articles after they are edited and typeset. Articles are then assigned page numbers and published in an issue. Issues of  RSC Pharmaceutics are published every other month.

See our most recent issue .

Ethical Requirements

RSC Pharmaceutics authors, editors, reviewers and published works are required to uphold the Royal Society of Chemistry’s ethical standards . The Royal Society of Chemistry is a member of the Committee on Publication Ethics (COPE) and our ethical standards follow COPE’s core practices and best practice guidelines . In cases where these guidelines are breached or appear to be so, the Royal Society of Chemistry will consult with COPE guidelines and act accordingly.

When a study involves the use of live animals or human subjects, authors must include in the 'methods/experimental' section of the manuscript a statement that all experiments were performed in compliance with the author’s institute’s policy on animal use and ethics; where possible, details of compliance with national or international laws or guidelines should be included. The statement must name the institutional/local ethics committee which has approved the study; where possible, the approval or case number should be provided. A statement that informed consent was obtained for any experimentation with human subjects is required. Reviewers may be asked to comment specifically on any cases in which concerns arise.

For further guidance on author responsibilities and code of conduct, which apply to RSC Pharmaceutics and to all manuscripts submitted to Royal Society of Chemistry journals, please visit our author hub .

Open Access

As a gold open access journal, RSC Pharmaceutics  can maximise the potential and visibility of your publications. Our articles are free to read, access and cite by anyone around the world. We are also covering all article processing charges until mid-2026, so you can publish with us for free.

We offer RSC Pharmaceutic s authors a choice of two Creative Commons licences: CC BY or CC BY NC. Publication under these licences means that authors retain the copyright of their article, but users are allowed to read, download, copy, distribute, print, search, or link to the full texts of articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. Read our open access statement for further information.

All published articles are deposited with LOCKSS, CLOCKSS, Portico and the British Library for archiving.

Dive into the benefits of open access publishing:

Find out more about open access publishing routes

Explore Royal Society of Chemistry open access journals

Read our Researchers’ voice report in response to Plan S

Subscription information

RSC Pharmaceutics is fully gold open access – articles can be downloaded free from the website with no barriers to access.

Online only: ISSN 2976-8713

Copyright is retained by authors when an open access licence is accepted, as with our standard licence to publish agreement. Full and accurate attribution to the original author is required for any re-use of the work. Find out more about copyright, licences and re-use permission .

**The median time from submission to first decision including manuscripts rejected without peer review from the previous calendar year

***The median time from submission to first decision for peer-reviewed manuscripts from the previous calendar year

Get email alerts about RSC Pharmaceutics

For the latest editorial board news, scope details and announcements, sign up for news and issue alerts by using the form below. For any other queries, please get in touch using the contact us form on this page.

Please update your browser to a newer version to use this form.

Terms and conditions

Please tick this box to acknowledge that:

• You have read, understood and accept the terms and conditions .
• We need to collect and manage your personal data in order to provide this service. Our privacy statement explains how we do this.

Information

• Author Services

Initiatives

You are accessing a machine-readable page. In order to be human-readable, please install an RSS reader.

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess .

Feature papers represent the most advanced research with significant potential for high impact in the field. A Feature Paper should be a substantial original Article that involves several techniques or approaches, provides an outlook for future research directions and describes possible research applications.

Feature papers are submitted upon individual invitation or recommendation by the scientific editors and must receive positive feedback from the reviewers.

Editor’s Choice articles are based on recommendations by the scientific editors of MDPI journals from around the world. Editors select a small number of articles recently published in the journal that they believe will be particularly interesting to readers, or important in the respective research area. The aim is to provide a snapshot of some of the most exciting work published in the various research areas of the journal.

Original Submission Date Received: .

• Active Journals
• Find a Journal
• Proceedings Series
• For Authors
• For Reviewers
• For Editors
• For Librarians
• For Publishers
• For Societies
• For Conference Organizers
• Open Access Policy
• Institutional Open Access Program
• Special Issues Guidelines
• Editorial Process
• Research and Publication Ethics
• Article Processing Charges
• Testimonials
• Preprints.org
• SciProfiles
• Encyclopedia

Article Menu

• Subscribe SciFeed
• PubMed/Medline
• Google Scholar
• on Google Scholar
• Table of Contents

Find support for a specific problem in the support section of our website.

Please let us know what you think of our products and services.

Visit our dedicated information section to learn more about MDPI.

JSmol Viewer

Recent trends in pharmaceutical analytical chemistry.

Conflicts of Interest

• Yao, W.; Yu, L.; Fan, W.; Shi, X.; Liu, L.; Li, Y.; Qin, X.; Rao, C.; Wang, J. A Cell-Based Strategy for Bioactivity Determination of Long-Acting Fc-Fusion Recombinant Human Growth Hormone. Molecules 2019 , 24 , 1389. [ Google Scholar ] [ CrossRef ] [ PubMed ] [ Green Version ]
• Song, Y.; Zhou, Y.; Yan, X.-T.; Bi, J.-B.; Qiu, X.; Bian, Y.; Wang, K.-F.; Zhang, Y.; Feng, X.-S. Pharmacokinetics and Tissue Distribution of Alnustone in Rats after Intravenous Administration by Liquid Chromatography-Mass Spectrometry. Molecules 2019 , 24 , 3183. [ Google Scholar ] [ CrossRef ] [ PubMed ] [ Green Version ]
• Song, Y.; Zhang, Y.; Duan, X.-Y.; Cui, D.-W.; Qiu, X.; Bian, Y.; Wang, K.-F.; Feng, X.-S. Pharmacokinetics and Tissue Distribution of Anwuligan in Rats after Intravenous and Intragastric Administration by Liquid Chromatography-Mass Spectrometry. Molecules 2019 , 25 , 39. [ Google Scholar ] [ CrossRef ] [ PubMed ] [ Green Version ]
• Song, Y.; Zhang, Y.; Zhang, W.-P.; Zhang, B.-Z.; Wang, K.-F.; Feng, X.-S. Interaction Effects between Doxorubicin and Hernandezine on the Pharmacokinetics by Liquid Chromatography Coupled with Mass Spectrometry. Molecules 2019 , 24 , 3622. [ Google Scholar ] [ CrossRef ] [ PubMed ] [ Green Version ]
• Ezzeldin, E.; Iqbal, M.; Asiri, Y.A.; Ali, A.A.; Alam, P.; El-Nahhas, T. A Hydrophilic Interaction Liquid Chromatography–Tandem Mass Spectrometry Quantitative Method for Determination of Baricitinib in Plasma, and Its Application in a Pharmacokinetic Study in Rats. Molecules 2020 , 25 , 1600. [ Google Scholar ] [ CrossRef ] [ PubMed ] [ Green Version ]
• Zhao, N.; Tan, H.R.; Chen, Q.L.; Sun, Q.; Wang, L.; Song, Y.; Olounfeh, K.M.; Meng, F.H. Development and Validation of a Sensitive UHPLC-MS/MS Method for the Measurement of Gardneramine in Rat Plasma and Tissues and its Application to Pharmacokinetics and Tissue Distribution Study. Molecules 2019 , 24 , 3953. [ Google Scholar ] [ CrossRef ] [ PubMed ] [ Green Version ]
• Brusač, E.; Jeličić, M.L.; Amidžić Klarić, D.; Nigović, B.; Turk, N.; Klarić, I.; Mornar, A. Pharmacokinetic Profiling and Simultaneous Determination of Thiopurine Immunosuppressants and Folic Acid by Chromatographic Methods. Molecules 2019 , 24 , 3469. [ Google Scholar ] [ CrossRef ] [ PubMed ] [ Green Version ]
• Tzanavaras, P.D.; Papadimitriou, S.; Zacharis, C.K. Automated Stopped-Flow Fluorimetric Sensor for Biologically Active Adamantane Derivatives Based on Zone Fluidics. Molecules 2019 , 24 , 3975. [ Google Scholar ] [ CrossRef ] [ PubMed ] [ Green Version ]
• Funaki, A.; Horikoshi, Y.; Kobayashi, T.; Masadome, T. Determination of Polyhexamethylene Biguanide Hydrochloride Using a Lactone-Rhodamine B-Based Fluorescence Optode. Molecules 2020 , 25 , 262. [ Google Scholar ] [ CrossRef ] [ PubMed ] [ Green Version ]
• Ahmad, S.M.; Oliveira, M.N.; Neng, N.R.; Nogueira, J.M.F. A Fast and Validated High Throughput Bar Adsorptive Microextraction (HT-BAµE) Method for the Determination of Ketamine and Norketamine in Urine Samples. Molecules 2020 , 25 , 1438. [ Google Scholar ] [ CrossRef ] [ PubMed ] [ Green Version ]
• Tsanaktsidou, E.; Karavasili, C.; Zacharis, C.K.; Fatouros, D.G.; Markopoulou, C.K. Partial least square model (PLS) as a tool to predict the diffusion of steroids across artificial membranes. Molecules 2020 . [ Google Scholar ] [ CrossRef ] [ PubMed ] [ Green Version ]
• Wu, N.; Balayssac, S.; Danoun, S.; Malet-Martino, M.; Gilard, V. Chemometric Analysis of Low-field 1H NMR Spectra for Unveiling Adulteration of Slimming Dietary Supplements by Pharmaceutical Compounds. Molecules 2020 , 25 , 1193. [ Google Scholar ] [ CrossRef ] [ PubMed ] [ Green Version ]

Share and Cite

Zacharis, C.K.; Markopoulou, C.K. Recent Trends in Pharmaceutical Analytical Chemistry. Molecules 2020 , 25 , 3560. https://doi.org/10.3390/molecules25163560

Zacharis CK, Markopoulou CK. Recent Trends in Pharmaceutical Analytical Chemistry. Molecules . 2020; 25(16):3560. https://doi.org/10.3390/molecules25163560

Zacharis, Constantinos K., and Catherine K. Markopoulou. 2020. "Recent Trends in Pharmaceutical Analytical Chemistry" Molecules 25, no. 16: 3560. https://doi.org/10.3390/molecules25163560

Article Metrics

Article access statistics, further information, mdpi initiatives, follow mdpi.

Subscribe to receive issue release notifications and newsletters from MDPI journals

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

• View all journals

Drug discovery articles from across Nature Portfolio

Drug discovery is the process through which potential new medicines are identified. It involves a wide range of scientific disciplines, including biology, chemistry and pharmacology.

Cardioprotective effects of glatiramer acetate after ischemic myocardial injury

Glatiramer acetate, a drug with an established history of treating multiple sclerosis in clinical practice, improves cardiac function in rodent models of myocardial infarction and ischemic heart failure.

• Ulrich Hofmann
• Stefan Frantz

AI-recognized mitochondrial phenotype enables identification of drug targets

Revealing a drug’s mechanism of action (MOA) is costly and time-consuming. In this study, we used deep learning to extract temporal mitochondrial phenotypic features after exposure to drugs with known MOAs using re-identification algorithms. The trained model could then predict the MOAs of unidentified substances, facilitating phenotypic screening-based drug discovery and repurposing.

Machine learning trims the peptide drug design process to a sweet spot

Drugs that target peptide hormone receptors are of great interest in the treatment of type 2 diabetes. In spite of limited data and vast design spaces, a bespoke computational pipeline has designed peptides that target two receptors with high potency.

• Chloe E. Markey
• Daniel Reker

Related Subjects

• Business strategy in drug development
• Diagnostics
• Drug delivery
• Drug regulation
• Drug safety
• Drug screening
• Medicinal chemistry
• Pharmaceutics
• Pharmacology
• Target identification
• Target validation

Latest Research and Reviews

PharmaBench: Enhancing ADMET benchmarks with large language models

• Zhangming Niu
• Xianglu Xiao
• Hongming Chen

The influence of marine fungal meroterpenoid meroantarctine A toward HaCaT keratinocytes infected with Staphylococcus aureus

• Ekaterina A. Chingizova
• Artur R. Chingizov
• Ekaterina A. Yurchenko

Anti-liver tumor ingredient exploration and validation of Elephantopus tomentosus Linn. by combining in silico and in vitro experiments

• Zhihao Zeng
• Canchao Jia

Comprehensive detection and characterization of human druggable pockets through binding site descriptors

PocketVec is a computational strategy to generate protein binding site descriptors through inverse virtual screening, which the authors use to systematically explore the human proteome and to characterize over 32,000 druggable pockets.

• Arnau Comajuncosa-Creus
• Guillem Jorba
• Patrick Aloy

Activated factor X delivered by adeno-associated virus significantly inhibited bleeding and alleviated hemophilic synovitis in hemophilic mice

• Feixu Zhang
• Xinyue Zhou

Synthesis, biological evaluation and molecular modeling studies of methyl indole-isoxazole carbohydrazide derivatives as multi-target anti-Alzheimer’s agents

• Parisa Nikfar
• Seyedeh Sara Mirfazli

News and Comment

Neurons give metastatic cells a push.

• M. Teresa Villanueva

“Clone-specific” antibody-drug conjugates: an innovative strategy in the treatment of T-cell cancers

• Dennis Jungherz
• Philipp Lückemeier
• Marco Herling

Still controversial issues on assessing anhedonia in experimental modeling of depression

• Simona Scheggi

Evolving therapeutic paradigms in ocular graft-versus-host disease

• Mouayad Masalkhi
• Noura Wahoud
• Ezzat Elhassadi

Quick links

• Explore articles by subject
• Guide to authors
• Editorial policies

Pharmaceutical Research - Science topic

• Recruit researchers
• Join for free
• Login Email Tip: Most researchers use their institutional email address as their ResearchGate login Password Forgot password? Keep me logged in Log in or Continue with Google Welcome back! Please log in. Email · Hint Tip: Most researchers use their institutional email address as their ResearchGate login Password Forgot password? Keep me logged in Log in or Continue with Google No account? Sign up